SPX4,280.15+72.88 1.73%
DIA337.83+4.12 1.23%
IXIC13,047.19+267.27 2.09%

Pfizer/BioNTech Start Ohase 2 Trial For COVID-19 Vaccine Against Omicron Subvariant

Benzinga · 07/27/2022 13:48
  • Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTXinitiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. 
  • This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. 
  • Related: BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac.
  • The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified to increase the magnitude and breadth of the immune response that could better protect against COVID-19. 
  • The companies plan to evaluate this as the first of multiple vaccine candidates with an enhanced design.
  • BNT162b5 will be evaluated in a U.S.-based study enrolling approximately 200 participants aged between 18 and 55 who have received one booster dose of a U.S.-authorized COVID-19 vaccine at least 90 days before their first study visit. 
  • Price Action: PFE shares are down 1.25% at $51.65, and BNTX stock is down 2.72% at $155.38 during the market session on the last check Wednesday.
  • Photo by x3 from Pixabay